Elite Pharma Catalyst: --4 quarters of rising

Elite Pharma Catalyst:

--4 quarters of rising revenues
--Lodrane 24 returning
--Lodrane D  OTC  gaining market share
--operations nearing cash flow positive
--CEO loaned the co. 1 million dollars unsecured (non-dilutive)
--interest paid in full on all loans
--ELI-216 ART opiods still a priority, closer along than people think
--2nd patent for ELI-216(April 2013) giving Elite a hammerlock on 2 bead ART

--partner for ELI-216 could beannounced any day                                                                                                                                                                                                                                                                                             
--Novel net worth growing 31 FDA approved drugs
--10% ownership in Novel Labs, Novel has approached Elite for monetization
--estimates for 10% of Novel range from 10 million to  100 million
--Elites debt of 3.5 million will be eliminated with Novel sale
--current launched drugs continue to gain market share
--2 drug launchs imminent, 15 and 30 phentermine (May 2013)
--BE and PK studies progressing, some near completion
--New Jersey tax credits approaching 1 million dollars
--Phase III trials for AR CR OXY could begin tomorrow
--impressive pipeline
--multiple partners
--contracting deals
--Hong Kong NDA progressing
--MIK-001 possible improved Embeda
--first of 8 Epic drugs due out anytime
--Tagi
--undisclosed ANDA's could come out any day
--micro capsule patent progressing, smallest size in the industry
--Naltrexone launching soon(May-June 2013)
--JT's goal is to have a complete line of abuse resistant opiods
--return to NASDAQ exchange
--modular technology good for all opiods